Tuesday's election eliminated some uncertainty around health-care reform, but the market is still undervaluing several firms in the sector, say Morningstar's Alex Morozov and Matt Coffina.
Among the companies that Morningstar analysts cover, these 15 are priced for perfection.
Our Ultimate Stock-Pickers Index continues to beat the market even as relatively few of our top managers are outperforming the S&P 500.
A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.
Morningstar markets editor Jeremy Glaser sizes up the scenarios on the fiscal cliff, health-care reform, Fed policy, bank regulation, and more following this week's election.
This week: A Greek revival, a new frontier, easing Fed concerns, and an artistically volatile stock.
Recent sell-off provides dozens of buying opportunities.
Despite the Fed taper, a U.S. economy struggling to shake off the winter blues, and a slowing China, stocks continued their remarkable winning streak from April through June.
Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.